Aggarwal, R. R., Dooley, K., Hillman, D. W., Xiao, H., Picus, J., Taplin, M.-E., … Morris, M. J. (2023). Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Aggarwal, Rahul Raj, Katherine Dooley, David W. Hillman, Han Xiao, Joel Picus, Mary-Ellen Taplin, Tanya B. Dorff, et al. “Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Aggarwal RR, Dooley K, Hillman DW, Xiao H, Picus J, Taplin M-E, et al. Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19). In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Aggarwal, Rahul Raj, et al. “Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19).” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Aggarwal RR, Dooley K, Hillman DW, Xiao H, Picus J, Taplin M-E, Dorff TB, Appleman LJ, Weckstein DJ, Patnaik A, Bryce AH, Shevrin DH, Mohler JL, Anderson DM, Heller G, Halabi S, Tan A, Eggener SE, Ryan CJ, Morris MJ. Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19). JOURNAL OF CLINICAL ONCOLOGY. 2023.